SCHEDULE: Armistice Capital Discloses Stake in Intelligent Bio Solutions

Armistice Capital, LLC and Steven Boyd have reported a 9.99% stake in Intelligent Bio Solutions Inc., holding 163,571 shares.

Summary

• Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, indicating beneficial ownership of 163,571 shares of Intelligent Bio Solutions Inc. common stock.
• This holding represents 9.99% of the class of securities.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may be deemed to beneficially own these shares.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports a change in beneficial ownership without providing operational or financial performance details of the underlying company.

Positives

• Armistice Capital, LLC and Steven Boyd have acquired a significant stake (9.99%) in Intelligent Bio Solutions Inc., potentially indicating confidence in the company's future prospects.
• The filing confirms the acquisition was made in the ordinary course of business, suggesting a standard investment strategy rather than a hostile takeover attempt.

Negatives

• The filing does not provide specific financial performance data or operational updates for Intelligent Bio Solutions Inc., limiting the assessment of the company's current health.

Risks

• The filing does not explicitly detail any risks associated with Intelligent Bio Solutions Inc. or the investment itself.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the future performance of Intelligent Bio Solutions Inc.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
• The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate a passive investment approach by institutional investors or significant shareholders, often in companies within the biotechnology or healthcare sectors, where Intelligent Bio Solutions Inc. operates.

Stakeholder Impact

• Shareholders of Intelligent Bio Solutions Inc. may see this as a sign of institutional interest, potentially influencing market perception.
• The acquisition by Armistice Capital, LLC and Steven Boyd, holding a significant stake, could lead to increased scrutiny or engagement with the company's management.

Next Steps

• Armistice Capital, LLC and Steven Boyd will continue to hold the reported shares.
• Future amendments to this Schedule 13G will be filed as required by regulations.

Key Dates

Keywords

Intelligent Bio Solutions Inc., Schedule 13G, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, Investment Management, SEC Filing